Is Clinical Trial Funding Affected by the Disjunction Effect During Election Years?
Introduction The U.S. pharmaceutical industry is significantly regulated by federal policy, which means that changes in government leadership, especially during election years, create uncertainty for companies. This uncertainty often leads to a reduction or delay in funding for long-term clinical trials as companies await regulatory and healthcare policy outcomes. The concept of the “disjunction effect,” […]